Dan Chinnapen

Daniel Chinnapen is an accomplished professional with extensive experience in biotechnology and medicinal research. Currently serving as the CEO of Phorum.AI since January 2024, Daniel also holds a position on the Scientific Advisory Board at Transcera. Daniel previously led target delivery efforts at Sail Biomedicines, focusing on circular RNA and novel vaccine delivery methods. As Chief Scientific Officer at Vantage, Daniel was instrumental in CBD manufacturing and process development. Academic roles include an Assistant Professorship at Harvard Medical School and scientific positions at Boston Children's Hospital, where Daniel advanced research in lipid-based therapies for lysosomal diseases. Daniel's educational background includes a Ph.D. in Molecular Biology and Biochemistry from Simon Fraser University, along with postdoctoral training at Harvard Medical School and the Massachusetts Institute of Technology.